These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32560435)

  • 1. Working within the Design Space: Do Our Static Process Characterization Methods Suffice?
    von Stosch M; Schenkendorf R; Geldhof G; Varsakelis C; Mariti M; Dessoy S; Vandercammen A; Pysik A; Sanders M
    Pharmaceutics; 2020 Jun; 12(6):. PubMed ID: 32560435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Question-based review for pharmaceutical development: An enhanced quality approach.
    Simões A; Veiga F; Vitorino C
    Eur J Pharm Biopharm; 2024 Feb; 195():114174. PubMed ID: 38160986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian approach to the ICH Q8 definition of design space.
    Peterson JJ
    J Biopharm Stat; 2008; 18(5):959-75. PubMed ID: 18781528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Information Processing: Rate-Based Investigation of Cell Physiological Changes along Design Space Development.
    Sagmeister P; Wechselberger P; Herwig C
    PDA J Pharm Sci Technol; 2012; 66(6):526-41. PubMed ID: 23183649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a Saccharomyces cerevisiae fermentation process for production of a therapeutic recombinant protein using a multivariate Bayesian approach.
    Fu Z; Baker D; Cheng A; Leighton J; Appelbaum E; Aon J
    Biotechnol Prog; 2016 May; 32(3):799-812. PubMed ID: 27095416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A quality by design approach for longitudinal quality attributes.
    Lebrun P; Giacoletti K; Scherder T; Rozet E; Boulanger B
    J Biopharm Stat; 2015; 25(2):247-59. PubMed ID: 25360720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Process characterization and Design Space definition.
    Hakemeyer C; McKnight N; St John R; Meier S; Trexler-Schmidt M; Kelley B; Zettl F; Puskeiler R; Kleinjans A; Lim F; Wurth C
    Biologicals; 2016 Sep; 44(5):306-18. PubMed ID: 27464992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling in the quality by design environment: Regulatory requirements and recommendations for design space and control strategy appointment.
    Djuris J; Djuric Z
    Int J Pharm; 2017 Nov; 533(2):346-356. PubMed ID: 28579542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
    J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design Space and Control Strategy for the Manufacturing of Wet Media Milled Drug Nanocrystal Suspensions by Adopting Mechanistic Process Modeling.
    Bitterlich A; Mihorko A; Juhnke M
    Pharmaceutics; 2024 Feb; 16(3):. PubMed ID: 38543222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining process design space for biotech products: case study of Pichia pastoris fermentation.
    Harms J; Wang X; Kim T; Yang X; Rathore AS
    Biotechnol Prog; 2008; 24(3):655-62. PubMed ID: 18412404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control Systems Engineering in Continuous Pharmaceutical Manufacturing May 20-21, 2014 Continuous Manufacturing Symposium.
    Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
    J Pharm Sci; 2015 Mar; 104(3):832-839. PubMed ID: 28756845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De-risking pharmaceutical tablet manufacture through process understanding, latent variable modeling, and optimization technologies.
    Muteki K; Swaminathan V; Sekulic SS; Reid GL
    AAPS PharmSciTech; 2011 Dec; 12(4):1324-34. PubMed ID: 21969245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Greedy design space construction based on regression and latent space extraction for pharmaceutical development.
    Tanabe S; Muraki T; Yaginuma K; Kim S; Kano M
    Int J Pharm; 2023 Jul; 642():123178. PubMed ID: 37364782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analytical procedure validation and the quality by design paradigm.
    Rozet E; Lebrun P; Michiels JF; Sondag P; Scherder T; Boulanger B
    J Biopharm Stat; 2015; 25(2):260-8. PubMed ID: 25357001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bayesian design space for analytical methods based on multivariate models and predictions.
    Lebrun P; Boulanger B; Debrus B; Lambert P; Hubert P
    J Biopharm Stat; 2013; 23(6):1330-51. PubMed ID: 24138435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of computational fluid dynamics as a tool for establishing process design space for mixing in a bioreactor.
    Rathore AS; Sharma C; Persad AA
    Biotechnol Prog; 2012; 28(2):382-91. PubMed ID: 22083975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
    Foffi G; Pastore A; Piazza F; Temussi PA
    Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Process Analytical Technology for Crystallization of Active Pharmaceutical Ingredients.
    Malwade CR; Qu H
    Curr Pharm Des; 2018; 24(21):2456-2472. PubMed ID: 29956616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.